Adaptation or Selection--mechanisms of Castration-resistant Prostate Cancer

Overview

Journal Nat Rev Urol

Specialty Urology

Date 2012 Dec 19

PMID 23247694

Citations 66

Authors

Yang Zong

Andrew S Goldstein

Affiliations

Soon will be listed here.

Abstract

Men with advanced prostate cancer are typically treated with hormonal therapy, which leads to tumour shrinkage. However, tumours relapse and develop into the lethal form of the disease, termed castration-resistant prostate cancer (CRPC). Two distinct, but not mutually exclusive, models have been proposed in the literature to describe the onset of CRPC: adaptation and selection. Although some studies indicate that tumour cells acquire new alterations that enable them to survive in the castrated state (adaptation), other research points to the outgrowth of rare, pre-existing cells capable of surviving hormonal therapy (selection). Targeting the cells that survive hormonal therapy--by either adaptation or selection--is necessary to prevent the development of CRPC. Current research is focused on not only understanding the cellular mechanisms of CRPC, but also defining critical pathways that can be targeted with combinatorial therapies in castration-resistant cancer cells.

Citing Articles

Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition.

Chang Y, Wang X, Yang J, Tien J, Mannan R, Cruz G Cell Rep Med. 2024; 5(10):101752.

PMID: 39353441 PMC: 11513842. DOI: 10.1016/j.xcrm.2024.101752.

Epigenetic roles of KDM3B and KDM3C in tumorigenesis and their therapeutic implications.

Yoo J, Kim G, Jeon Y, Lee S, Kwon S Cell Death Dis. 2024; 15(6):451.

PMID: 38926399 PMC: 11208531. DOI: 10.1038/s41419-024-06850-z.

Endoplasmic reticulum stress-related genes as prognostic and immunogenic biomarkers in prostate cancer.

Wan L, Fan Y, Wu T, Liu Y, Zhang R, Chen S Eur J Med Res. 2024; 29(1):242.

PMID: 38643190 PMC: 11031923. DOI: 10.1186/s40001-024-01818-3.

MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC.

Wang Y, Chen J, Gong L, Wang Y, Siltari A, Lou Y J Nanobiotechnology. 2024; 22(1):145.

PMID: 38566211 PMC: 10985917. DOI: 10.1186/s12951-024-02438-z.

Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis.

Gao W, Sun L, Gai J, Cao Y, Zhang S PLoS One. 2024; 19(1):e0297260.

PMID: 38227591 PMC: 10791000. DOI: 10.1371/journal.pone.0297260.

References

Glickman M, Sawyers C . Converting cancer therapies into cures: lessons from infectious diseases. Cell. 2012; 148(6):1089-98. PMC: 3465702. DOI: 10.1016/j.cell.2012.02.015. View

Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L . Androgen receptor mutations in prostate cancer. Cancer Res. 2000; 60(4):944-9. View

Choi N, Zhang B, Zhang L, Ittmann M, Xin L . Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell. 2012; 21(2):253-65. PMC: 3285423. DOI: 10.1016/j.ccr.2012.01.005. View

Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig Z, Cecchini M . Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells. 2012; 30(6):1076-86. DOI: 10.1002/stem.1087. View

Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K . The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 2004; 64(2):765-71. DOI: 10.1158/0008-5472.can-03-0130. View

Snoek R, Cheng H, Margiotti K, Wafa L, Wong C, Wong E . In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res. 2009; 15(1):39-47. DOI: 10.1158/1078-0432.CCR-08-1726. View

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross N, Rentsch C . In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate. 2009; 69(15):1683-93. DOI: 10.1002/pros.21018. View

Mousses S, Wagner U, Chen Y, Kim J, Bubendorf L, Bittner M . Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene. 2001; 20(46):6718-23. DOI: 10.1038/sj.onc.1204889. View

10.

Gao H, Ouyang X, Banach-Petrosky W, Shen M, Abate-Shen C . Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res. 2006; 66(16):7929-33. DOI: 10.1158/0008-5472.CAN-06-1637. View

11.

Cai C, He H, Chen S, Coleman I, Wang H, Fang Z . Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011; 20(4):457-71. PMC: 3225024. DOI: 10.1016/j.ccr.2011.09.001. View

12.

Van Bokhoven A, Varella-Garcia M, Korch C, Johannes W, Smith E, Miller H . Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003; 57(3):205-25. DOI: 10.1002/pros.10290. View

13.

Mohler J, Titus M, Bai S, Kennerley B, Lih F, Tomer K . Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res. 2011; 71(4):1486-96. PMC: 3075600. DOI: 10.1158/0008-5472.CAN-10-1343. View

14.

Gao H, Ouyang X, Banach-Petrosky W, Gerald W, Shen M, Abate-Shen C . Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A. 2006; 103(39):14477-82. PMC: 1599986. DOI: 10.1073/pnas.0606836103. View

15.

Lee L, Guan J, Qiu Y, Kung H . Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol. 2001; 21(24):8385-97. PMC: 100003. DOI: 10.1128/MCB.21.24.8385-8397.2001. View

16.

Wang X, Kruithof-de Julio M, Economides K, Walker D, Yu H, Halili M . A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009; 461(7263):495-500. PMC: 2800362. DOI: 10.1038/nature08361. View

17.

Scher H, Beer T, Higano C, Anand A, Taplin M, Efstathiou E . Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375(9724):1437-46. PMC: 2948179. DOI: 10.1016/S0140-6736(10)60172-9. View

18.

Hellerstedt B, Pienta K . The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002; 52(3):154-79. DOI: 10.3322/canjclin.52.3.154. View

19.

Hu R, Dunn T, Wei S, Isharwal S, Veltri R, Humphreys E . Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69(1):16-22. PMC: 2614301. DOI: 10.1158/0008-5472.CAN-08-2764. View

20.

Gomella L . Effective testosterone suppression for prostate cancer: is there a best castration therapy?. Rev Urol. 2009; 11(2):52-60. PMC: 2725306. View